Bir Dawn Carter 4
4 · REATA PHARMACEUTICALS INC · Filed Aug 1, 2023
Insider Transaction Report
Form 4
Bir Dawn Carter
VP, Chief Commercial Officer
Transactions
- Conversion
Class A common stock
2023-07-28+40,000→ 75,010 total - Exercise/Conversion
Class B common stock
2023-07-28$22.57/sh+40,000$902,800→ 40,000 total→ Class A common stock (40,000 underlying) - Sale
Class A common stock
2023-07-28$164.54/sh−40,000$6,581,428→ 35,010 total - Exercise/Conversion
Employee Stock Option (right to buy)
2023-07-28−40,000→ 0 totalExercise: $22.57Exp: 2026-12-07→ Class B common stock (40,000 underlying) - Conversion
Class B common stock
2023-07-28−40,000→ 0 total→ Class A common stock (40,000 underlying)
Footnotes (4)
- [F1]The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
- [F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2023.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $164.25 to $165.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The options vested in twenty equal quarterly installments beginning on March 7, 2017.